Data monitoring committee recommends continuation of SGX301 trial in cutaneous T-cell lymphoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Soligenix Inc. said it has received a positive recommendation from the independent Data Monitoring Committee to continue enrolling into the company’s phase III “Fluorescent Light Activated Synthetic Hypericin” study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login